A Prospective, Multicenter, Observational Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated with Ixazomib plus Lenalidomide and Dexamethasone
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 03 Jul 2019
Price : $35 *
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Takeda Pharma
- 14 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 09 Jul 2018 Planned primary completion date changed from 28 Feb 2021 to 31 Mar 2021.
- 09 Jul 2018 Planned End Date changed from 28 Feb 2021 to 31 Mar 2021.